Hims & Hers Health Stock +9% Monday, Joining S&P 600 SmallCap
Hims & Hers Health Stock +9% Monday, Joining S&P 600 SmallCap
Hims & Hers Health shares also appear to be bouncing back after falling toward the end of last week after the U.S. Food and Drug Administration removed Eli Lilly's Mounjaro and Zepbound from the weight-loss and diabetes drugs shortage list.$Hims & Hers Health (HIMS.US)$ shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this week.
$Hims & Hers Health (HIMS.US)$ 股票週一交易走高。該公司本週將加入標普小型股600指數。
Hims & Hers Health shares are moving higher in anticipation of the company joining the S&P SmallCap 600 prior to the opening of trading on Wednesday. Hims & Hers Health shares jumped about 5% on the announcement late last week.
Hims & Hers Health股票上漲，預計該公司將在週三開盤前加入標普小型股600指數。Hims & Hers Health股票在上週末的公告後暴漲約5%。
Hims & Hers will replace Vector Group, which is being acquired by JT Group in a deal expected to close pending final conditions.
Hims & Hers將取代準備在最終條件滿足後由Jt Group收購的Vector Group。
Hims & Hers Health shares also appear to be bouncing back after falling toward the end of last week after the U.S. Food and Drug Administration removed Eli Lilly's Mounjaro and Zepbound from the weight-loss and diabetes drugs shortage list.
Hims & Hers Health的股價在上週末降至最低後似乎出現反彈，此前美國食品和藥物管理局將Eli Lilly的Mounjaro和Zepbound從減肥和糖尿病藥物短缺名單中撤下。
The FDA said in a statement last week that Eli Lilly's supply can now keep up with current demand. Mounjaro had been on the regulator's shortage list since late 2022. Zepbound had been on the list since April. Hims & Hers Health shares fell on the news as the company sells cheaper versions, known as compounded drugs.
美國食品和藥品管理局上週在一份聲明中表示，Eli Lilly的供應現在可以滿足目前的需求。Mounjaro自2022年底以來一直在監管機構的短缺名單上。Zepbound自4月以來一直在該名單上。Hims & Hers Health的股價因公司銷售價格較便宜的版本，也就是複方藥品而下跌。